During the past decade, Brüderkrankenhaus St. Josef Paderborn conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 5 clinical trials were completed, i.e. on average, 38.5% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 2 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Brüderkrankenhaus St. Josef Paderborn" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "German CLL Study Group" with 4 trials sponsored, "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 2 trials sponsored, "University of Jena" with 2 trials sponsored and "AIO-Studien-gGmbH" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Brüderkrankenhaus St. Josef Paderborn" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "CAPNETZ Stiftung" with 1 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Brüderkrankenhaus St. Josef Paderborn" are "Chronic Lymphoid Leukemia" (2 trials), "Chronic Myeloid Leukemia" (2 trials), "Lymphoma" (2 trials), "Advanced or Metastatic Renal Cell Carcinoma" (1 trials) and "Aplastic Anaemia" (1 trials). Many other conditions were trialed in "Brüderkrankenhaus St. Josef Paderborn" in a lesser frequency.

Most popular intervention types in "Brüderkrankenhaus St. Josef Paderborn" are "Drug" (19 trials), "Biological" (5 trials), "Device" (3 trials), "Radiation" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Obinutuzumab" (5 trials), "Atezolizumab" (4 trials), "Rituximab" (3 trials), "Venetoclax" (3 trials) and "Acalabrutinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Brüderkrankenhaus St. Josef Paderborn" are 25 trials for "All" genders.

Currently, there are NaN active trials in "Brüderkrankenhaus St. Josef Paderborn". undefined are not yet recruiting, 6 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Brüderkrankenhaus St. Josef Paderborn, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Brüderkrankenhaus St. Josef Paderborn, 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Brüderkrankenhaus St. Josef Paderborn has several departments that took part in Clinical trials: "Brüderkrankenhaus St. Josef Paderborn, Klinik für Hämatologie und Onkologie" - 2 trials